ACE-1702 is under clinical development by Acepodia and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACE-1702’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACE-1702 is under development for the treatment of HER2-expressing solid tumors.The drug candidate is developed based on ACC (antibody-cell conjugation) technology to develop a series of antibody-conjugated effector cells (ACE). It is administered through intravenous route.
It was under development for the treatment of recurrent ovarian cancer, endometrial cancer, gastric cancer and HER-2 positive breast cancer.
Acepodia is a biotechnology company that develops cell therapies to treat cancers. It is investigating ACE1702, an antibody-conjugated NK (natural killer) cell therapy targeting HER2-expressed solid tumors; ACE1831 drug against CD20-indicated hematological cancers; ACE1708 an off-the-shelf NK-like gamma delta T therapy for PD-L1 expressed solid tumors. The company is also evaluating ACE1975 and ACE2107 antibodies against solid tumors and hematological malignancies; ACE2023 for the treatment of hepatocellular carcinoma (HCC); and ACE2146 for solid tumors. Acepodia utilizes its antibody-cell conjugation (ACC) technology platform to develop immunotherapies. The company has operational presence in New Taipei City, Taiwan. Acepodia is headquartered in San Mateo, California, the US.
For a complete picture of ACE-1702’s drug-specific PTSR and LoA scores, buy the report here.